ABSTRACT
Objective Assess whether biomarkers of systemic inflammation are associated with HIV acquisition or with the timing of ART initiation (“immediate”, at diagnosis, versus “deferred”, at 24 weeks postdiagnosis) in men-who-have-sex-with-men (MSM) and transgender women.
Design A retrospective study comparing inflammatory biomarkers in participants’ specimens collected before and after ≥2 years of effective ART.
Methods Inflammatory biomarkers were measured in four longitudinally collected plasma specimens, including two plasma specimens collected from each participant before and two after HIV acquisition and confirmed ART-suppression. Biomarkers were quantified by enzyme-linked immuno-assay or Meso Scale Discovery. Statistical measures compared intra-participant and between-group changes in biomarkers.
Results Across 50 participants, the levels of C-reactive protein (CRP), monocyte chemo-attractant protein-1, tumor necrosis factor-α and interferon gamma-induced protein-10 significantly increased while leptin and lipopolysaccharide binding protein (LBP) significantly decreased following HIV infection. Randomization to deferred-ART initiation was associated with greater increases in CRP and no decreases in LBP. Multiple biomarkers varied significantly within participants’ two pre-infection or two post-ART-suppression specimens.
Conclusions Acquisition of HIV appeared to induce systemic inflammation, with elevation of biomarkers previously associated with infections and cardiovascular disease. Initiation of ART during the early weeks of infection tempered the increase in pro-inflammatory biomarkers compared to those who delayed ART for ∼24 weeks after HIV diagnosis, perhaps because immediate-ART limited the size of the HIV reservoir or limited immune dysregulation. Some but not all biomarkers appeared sufficiently stable to assess intraparticipant changes over time. Given that pro-inflammatory biomarkers predict multiple co-morbidities, our findings suggest that immediate-ART initiation may improve health outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The project was funded by NIH R01 DA040532 (ACD). Additional support came from the Molecular Profiling and Computational Biology Core of the University of Washington and Fred Hutch Center for AIDS Research (award number P30 AI027757), from the Laboratory Core of International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT) UM1 AI106716 (Subaward: LMF). This work was also supported by the National Center For Advancing Translational Sciences of the National Institutes of Health under Award Number KL2 TR002317 (GG). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional review boards at Fred Hutchison Cancer Research Center, Seattle, WA and Asociación Civil Impacta Salud y Educación, Lima, Perú approved this study. Written informed consent was obtained from all participants.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Summary data available in the manuscript. Participant level data is stored at Fred Hutch and de-identified data is available by request of Ann Duerr
